PAR 20.4% 32.5¢ paradigm biopharmaceuticals limited..

Ann: Elite sportspeople successfully treated with PPS, page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 547 Posts.
    lightbulb Created with Sketch. 5
    Hi Tommy, My wife is in a clinical trial for PPS and it is proving a great success to her. She has had bad knees since her late teens - 2 reconstructions, 5 other meniscus/cartlidge/cleanout surgeries. Had constant knee pain for years, to the point where she was contemplating suicide. A few years ago we tried stem cell treatment which involved reinjections of removed stem cells from her fat cells. Helped for 2 years but wasn't the sliver bullet we were hoping for, especially for the $12k it cost (yikes!). This has been a much greater success, 12 subcutaneous injections of PPS in her belly over 6 weeks, just completed and knee pain much improved, now she only get sore knees after exercise or being on her feet all day, rather than constantly as it was before. Very promising. Sorry I don't know any details on the dosage she was getting, and of course she could be in the placebo group but I don't think so.

    I was trying to get hold of PPS for her before she got onto the clinical trial and was about to source some from a veterinarian supply website in the US but dropped it when the clinical trial came up. Good luck.
    cheers
    toscanunan
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
32.5¢
Change
0.055(20.4%)
Mkt cap ! $82.30M
Open High Low Value Volume
27.5¢ 33.5¢ 27.5¢ $1.328M 4.323M

Buyers (Bids)

No. Vol. Price($)
1 4624 32.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.0¢ 152597 4
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.